Anavex doses first patient in Phase 2 Rett Syndrome trial

Anavex Life Sciences (NASDAQ:AVXL) dosed the first patient in its Phase 2 trial of ANAVEX2-73 for the treatment of Rett syndrome.

Rett syndrome is a genetic neurodevelopmental disorder caused by mutations in the MECP2 gene, and is characterized by severe physical and intellectual impairments. The only treatment for Rett syndrome is symptomatic; there is currently no cure.

ANAVEX2-73, which has received FDA orphan drug designation, is an orally-administered liquid designed to activate the sigma-1 receptor protein, which is involved in restoring homeostasis.

“We have made great effort to develop a patient-centric clinical trial, using our learnings from broad dialogue with the Rett syndrome community,” Christopher Missling, Anavex’s president and CEO, said in a statement.

The trial will enroll some 30 patients 18 years of age and older to receive ANAVEX2-73 once daily, or placebo, for up to seven weeks.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.